Association between cardiovascular vs. Non-cardiovascular co-morbidities and outcomes in heart failure with preserved ejection fraction

European Journal of Heart Failure

Volumn 16, Issue 9, 2014, Pages 992-1001

  Lund, Lars H ^a   Donal, Erwan ^b,c   Oger, Emmanuel ^d   Hage, Camilla ^a   Persson, Hans ^e,f   Haugen Löfman, Ida ^a   Ennezat, Pierre Vladimir ^g   Sportouch Dukhan, Catherine ^h   Drouet, Elodie ⁱ   Daubert, Jean Claude ^b,c   Linde, Cecilia ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b RENNES UNIVERSITY HOSPITAL   (France)

^c UNIVERSITÉ DE RENNES 1   (France)

^d UNIVERSITÉ DE RENNES 1   (France)

^e Sweden Karolinska Institutet Department of Clinical Sciences Danderyd Hospital Stressrehab FoU Danderyd   (Sweden)

^f DANDERYD HOSPITAL   (Sweden)

^g LILLE UNIVERSITY HOSPITAL   (France)

^h MONTPELLIER UNIVERSITY HOSPITAL   (France)

ⁱ Societe Francaise de Cardiologie   (France)

Author keywords

Co morbidity; Diastolic function; Diastolic heart failure; Heart failure with preserved ejection fraction; Outcomes

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; ANGIOTENSIN ANTAGONIST; ANTICOAGULANT AGENT; BRAIN NATRIURETIC PEPTIDE; POTASSIUM; POTASSIUM SPARING DIURETIC AGENT; SODIUM;

AGE; AGED; ANEMIA; AREA UNDER THE CURVE; ARTICLE; COHORT ANALYSIS; COMORBIDITY; CORONARY ARTERY DISEASE; DEATH; DIABETES MELLITUS; DIAGNOSTIC TEST ACCURACY STUDY; DISEASE ASSOCIATION; FAINTNESS; FEMALE; FOLLOW UP; FRAMINGHAM RISK SCORE; HEART ATRIUM FIBRILLATION; HEART ATRIUM FLUTTER; HEART FAILURE WITH PRESERVED EJECTION FRACTION; HOSPITALIZATION; HUMAN; HYPERTENSION; KIDNEY DYSFUNCTION; LUNG DISEASE; MAJOR CLINICAL STUDY; MALE; MALIGNANT NEOPLASTIC DISEASE; MEDICAL HISTORY; MORTALITY; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; POTASSIUM BLOOD LEVEL; PREDICTION; PREVALENCE; PROGNOSIS; PROSPECTIVE STUDY; RECEIVER OPERATING CHARACTERISTIC; SODIUM BLOOD LEVEL; SURVIVAL RATE; SURVIVAL TIME; CLINICAL TRIAL; FRANCE; HEART FAILURE; HEART STROKE VOLUME; HEART VALVE DISEASES; KIDNEY DISEASES; LUNG DISEASES; MULTICENTER STUDY; PATHOPHYSIOLOGY; PHYSIOLOGY; RISK FACTOR; SWEDEN; TIME; TRENDS; VERY ELDERLY;

AGED; AGED, 80 AND OVER; COMORBIDITY; FEMALE; FOLLOW-UP STUDIES; FRANCE; HEART FAILURE; HEART VALVE DISEASES; HUMANS; KIDNEY DISEASES; LUNG DISEASES; MALE; PROGNOSIS; PROSPECTIVE STUDIES; RISK FACTORS; STROKE VOLUME; SWEDEN; TIME FACTORS;

EID: 84908234801     PISSN: 13889842     EISSN: 18790844     Source Type: Journal    
DOI: 10.1002/ejhf.137     Document Type: Article

References (35)

1. Vasan RS, Benjamin EJ, Levy D. Prevalence, clinical features and prognosis of diastolic heart failure: An epidemiologic perspective. J Am Coll Cardiol 1995;26:1565-1574.
2. Owan TE, Hodge DO, Herges RM, Jacobsen SJ, Roger VL, Redfield MM. Trends in prevalence and outcome of heart failure with preserved ejection fraction. N Engl J Med 2006;355:251-259.
3. Lenzen MJ, Scholteop Reimer WJ, Boersma E, Vantrimpont PJ, Follath F, Swedberg K, Cleland J, Komajda M. Differences between patients with a preserved and a depressed left ventricular function: A report from the EuroHeart Failure Survey. Eur Heart J 2004;25:1214-1220.
4. Somaratne JB, Berry C, McMurray JJ, Poppe KK, Doughty RN, Whalley GA. The prognostic significance of heart failure with preserved left ventricular ejection fraction: A literature-based meta-analysis. Eur J Heart Fail 2009;11:855-862.
5. Meta-analysis Global Group in Chronic Heart Failure (MAGGIC). The survival of patients with heart failure with preserved or reduced left ventricular ejection fraction: An individual patient data meta-analysis. Europ Heart J 2012;33:1750-1757.
6. Redfield MM, Jacobsen SJ, Burnett JC Jr, Mahoney DW, Bailey KR, Rodeheffer RJ. Burden of systolic and diastolic ventricular dysfunction in the community: Appreciating the scope of the heart failure epidemic. JAMA 2003;289:194-202.
7. Zile MR, Baicu CF, Gaasch WH. Diastolic heart failure-abnormalities in active relaxation and passive stiffness of the left ventricle. N Engl J Med 2004;350:1953-1959.
8. Campbell RT, Jhund PS, Castagno D, Hawkins NM, Petrie MC, McMurray JJ. What have we learned about patients with heart failure and preserved ejection fraction from DIG-PEF, CHARM-preserved, and I-PRESERVE? J Am Coll Cardiol 2012;60:2349-2356.
9. Lund LH, Benson L, Dahlstrom U, Edner M. Association between use of renin-angiotensin system antagonists and mortality in patients with heart failure and preserved ejection fraction. JAMA 2012;308:2108-2117.
10. Lund LH, Stahlberg M. Aldosterone inhibition in patients with heart failure with preserved ejection fraction. JAMA 2013;310:205.
11. Caruana L, Petrie MC, Davie AP, McMurray JJ. Do patients with suspected heart failure and preserved left ventricular systolic function suffer from 'diastolic heart failure' or from misdiagnosis? A prospective descriptive study. BMJ 2000;321:215-218.
12. Lam CS, Lyass A, Kraigher-Krainer E, Massaro JM, Lee DS, Ho JE, Levy D, Redfield MM, Pieske BM, Benjamin EJ, Vasan RS. Cardiac dysfunction and noncardiac dysfunction as precursors of heart failure with reduced and preserved ejection fraction in the community. Circulation 2011;124:24-30.
13. Lam CS, Donal E, Kraigher-Krainer E, Vasan RS. Epidemiology and clinical course of heart failure with preserved ejection fraction. Eur J Heart Fail 2011;13:18-28.
14. Ather S, Chan W, Bozkurt B, Aguilar D, Ramasubbu K, Zachariah AA, Wehrens XH, Deswal A. Impact of noncardiac comorbidities on morbidity and mortality in a predominantly male population with heart failure and preserved versus reduced ejection fraction. J Am Coll Cardiol 2012;59:998-1005.
15. Donal E, Lund LH, Linde C, Edner M, Lafitte S, Persson H, Bauer F, Ohrvik J, Ennezat PV, Hage C, Lofman I, Juilliere Y, Logeart D, Derumeaux G, Gueret P, Daubert JC. Rationale and design of the Karolinska-Rennes (KaRen) prospective study of dyssynchrony in heart failure with preserved ejection fraction. Eur J Heart Fail 2009;11:198-204.
16. McKee PA, Castelli WP, McNamara PM, Kannel WB. The natural history of congestive heart failure: The Framingham study. N Engl J Med 1971;285:1441-1446.
17. van Buuren S. Multiple imputation of discrete and continuous data by fully conditional specification. Stat Methods Med Res 2007;16:219-242.
18. Lin DY, Wei LJ, Ying Z. Checking the Cox model with cumulative sums of martingale-based residuals. Biometrika 1993;80:557-572.
19. Van Spall HG, Toren A, Kiss A, Fowler RA. Eligibility criteria of randomized controlled trials published in high-impact general medical journals: A systematic sampling review. JAMA 2007;297:1233-1240.
20. Donal E, Thebault C, Lund LH, Kervio G, Reynaud A, Simon T, Drouet E, Nonotte E, Linde C, Daubert JC. Heart failure with a preserved ejection fraction: Additive value of an exercise stress echocardiography. Eur Heart J Cardiovasc Imaging 2012;13:656-665.
21. Donal E, Lund LH, Oger E, Hage C, Persson H, Reynaud A, Ennezat PV, Bauer F, Sportouch-Dukhan C, Drouet E, Daubert JC, Linde C, on behalf of the KaRen Investigators. Baseline characteristics of patients with heart failure and preserved ejection fraction included in the Karolinska Rennes (KaRen) study. Arch Cardiovasc Dis 2011;107:112-121.
22. Pocock SJ, Ariti CA, McMurray JJ, Maggioni A, Kober L, Squire IB, Swedberg K, Dobson J, Poppe KK, Whalley GA, Doughty RN. Meta-Analysis Global Group in Chronic Heart Failure. Predicting survival in heart failure: A risk score based on 39 372 patients from 30 studies. Eur Heart J 2013;34:1404-1413.
23. Komajda M, Carson PE, Hetzel S, McKelvie R, McMurray J, Ptaszynska A, Zile MR, Demets D, Massie BM. Factors associated with outcome in heart failure with preserved ejection fraction: Findings from the Irbesartan in Heart Failure with Preserved Ejection Fraction Study (I-PRESERVE). Circ Heart Fail 2011;4:27-35.
24. Cleland JG, Tendera M, Adamus J, Freemantle N, Polonski L, Taylor J. The perindopril in elderly people with chronic heart failure (PEP-CHF) study. Eur Heart J 2006;27:2338-2345.
25. Yusuf S, Pfeffer MA, Swedberg K, Granger CB, Held P, McMurray JJ, Michelson EL, Olofsson B, Ostergren J. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: The CHARM-Preserved Trial. Lancet 2003;362:777-781.
26. Massie BM, Carson PE, McMurray JJ, Komajda M, McKelvie R, Zile MR, Anderson S, Donovan M, Iverson E, Staiger C, Ptaszynska A. Irbesartan in patients with heart failure and preserved ejection fraction. N Engl J Med 2008;359:2456-2467.
27. Teerlink JR, Cotter G, Davison BA, Felker GM, Filippatos G, Greenberg BH, Ponikowski P, Unemori E, Voors AA, Adams KF Jr, Dorobantu MI, Grinfeld LR, Jondeau G, Marmor A, Masip J, Pang PS, Werdan K, Teichman SL, Trapani A, Bush CA, Saini R, Schumacher C, Severin TM, Metra M, Investigators REiAHF. Serelaxin, recombinant human relaxin-2, for treatment of acute heart failure (RELAX-AHF): A randomised, placebo-controlled trial. Lancet 2013;381: 29-39.
28. Yancy CW, Lopatin M, Stevenson LW, DeMarco T, Fonarow GC. Clinical presentation, management, and in-hospital outcomes of patients admitted with acute decompensated heart failure with preserved systolic function: A report from the Acute Decompensated Heart Failure National Registry (ADHERE) Database. J Am Coll Cardiol 2006;47:76-84.
29. Steinberg BA, Zhao X, Heidenreich PA, Peterson ED, Bhatt DL, Cannon CP, Hernandez AF, Fonarow GC. Trends in patients hospitalized with heart failure and preserved left ventricular ejection fraction: prevalence, therapies, and outcomes. Circulation 2012;126:65-75.
30. Hawkins NM, Petrie MC, Jhund PS, Chalmers GW, Dunn FG, McMurray JJ. Heart failure and chronic obstructive pulmonary disease: diagnostic pitfalls and epidemiology. Eur J Heart Fail 2009;11:130-139.
31. Tribouilloy C, Rusinaru D, Mahjoub H, Souliere V, Levy F, Peltier M, Slama M, Massy Z. Prognosis of heart failure with preserved ejection fraction: A 5 year prospective population-based study. Eur Heart J 2008;29:339-347.
32. Lund LH, Jurga J, Edner M, Benson L, Dahlstrom U, Linde C, Alehagen U. Prevalence, correlates, and prognostic significance of QRS prolongation in heart failure with reduced and preserved ejection fraction. Eur Heart J 2013;34:529-539.
33. Groenveld HF, Januzzi JL, Damman K, vanWijngaarden J, Hillege HL, vanVeldhuisen DJ, vanderMeer P. Anemia and mortality in heart failure patients: A systematic review and meta-analysis. J Am Coll Cardiol 2008;52:818-827.
34. Paulus WJ, Tschope C. A novel paradigm for heart failure with preserved ejection fraction: comorbidities drive myocardial dysfunction and remodeling through coronary microvascular endothelial inflammation. J Am Coll Cardiol 2013;62:263-271.
35. Flather MD, Yusuf S, Kober L, Pfeffer M, Hall A, Murray G, Torp-Pedersen C, Ball S, Pogue J, Moye L, Braunwald E. Long-term ACE-inhibitor therapy in patients with heart failure or left-ventricular dysfunction: A systematic overview of data from individual patients. ACE-Inhibitor Myocardial Infarction Collaborative Group. Lancet 2000;355:1575-1581.